Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Get Quote
Search InvestCenter
Recent Quotes
ATAI Life Sciences N.V. - Common Shares
Lantern Pharma Inc. - Common Stock
The 2023 ETF Series Trust II GMO International Value ETF
Urgent.ly Inc. - Common Stock
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ATAI Life Sciences N.V. - Common Shares
(NQ:
ATAI
)
2.182
+0.072 (+3.39%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Jun 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ATAI Life Sciences N.V. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
June 15, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
June 04, 2025
Via
Benzinga
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
June 03, 2025
From
Halper Sadeh LLC
Via
Business Wire
Atai Life Sciences Stock Rockets On Merger Plans With Beckley Psytech; Retail Traders Eye Every Dip
June 02, 2025
The merger focuses on creating a combined company focused on psychedelic mental health therapies.
Via
Stocktwits
DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers
March 19, 2025
Via
Investor Brand Network
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
June 02, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in Upcoming Investor Conferences
May 29, 2025
From
atai Life Sciences
Via
GlobeNewswire
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
May 24, 2025
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
Via
Benzinga
Topics
Government
Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer
May 21, 2025
Atai Life Sciences shares surged 11.4% after Beckley Psytech reported encouraging Phase 2a results of its depression treatment
Via
Stocktwits
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
May 20, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
May 14, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
May 13, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
March 17, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
March 11, 2025
From
atai Life Sciences
Via
GlobeNewswire
Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk
March 05, 2025
Via
Investor Brand Network
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
March 05, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
February 20, 2025
From
atai Life Sciences
Via
GlobeNewswire
Veterans Turn to One Another for Help Using Psychedelics to Combat Mental Health Challenges
February 19, 2025
Via
Investor Brand Network
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
February 14, 2025
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
Via
Stocktwits
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 13, 2025
Via
Benzinga
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
February 13, 2025
Via
Benzinga
atai Life Sciences Announces Pricing of Public Offering of Common Shares
February 12, 2025
From
atai Life Sciences
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
February 12, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
atai Life Sciences Announces Proposed Public Offering of Common Shares
February 12, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
January 28, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
January 10, 2025
From
atai Life Sciences
Via
GlobeNewswire
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
November 15, 2024
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Via
Investor's Business Daily
Topics
Government
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
November 13, 2024
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.
Via
Benzinga
Topics
Artificial Intelligence
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
November 13, 2024
Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.